Brain Neurotherapy Bio, Inc.
Clinical trials sponsored by Brain Neurotherapy Bio, Inc., explained in plain language.
-
New gene therapy aims to slow Parkinson's progression
Disease control OngoingThis early-stage study tests a gene therapy called AAV2-GDNF in 11 people with Parkinson's disease. The treatment delivers a protein that helps protect brain cells. The main goal is to check safety, but researchers will also look at whether it improves movement symptoms.
Phase: PHASE1 • Sponsor: Brain Neurotherapy Bio, Inc. • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
Experimental gene therapy tested for rare brain disease
Disease control OngoingThis early-stage study tests whether a gene therapy called AAV2-GDNF is safe for people with multiple system atrophy (MSA), a rare and serious brain disorder. Nine adults aged 35-75 with MSA will receive either the gene therapy or a placebo. The main goal is to check for side eff…
Phase: PHASE1 • Sponsor: Brain Neurotherapy Bio, Inc. • Aim: Disease control
Last updated May 20, 2026 11:56 UTC